Table 2.
Responses to chemotherapy stratified for type and treatment.
| Follow-up | Parameter | Vinorelbine (n = 14) |
Docetaxel (n = 12) |
|---|---|---|---|
| 3 mo | PSA | SD: 4 PR: 8 DP:2 | SD: 6 PR: 4 DP:2 |
| Clinical | SD: 4 PR: 9 DP:1 | SD: 7 PR: 3 DP:2 | |
| Imaging | SD: 4 PR: 8 DP:2 | SD: 6 PR: 4 DP:2 | |
| 6 mo | PSA | SD: 2 PR: 6 DP:4 | SD: 4 PR: 3 DP:3 |
| Clinical | SD: 3 PR: 6 DP:3 | SD: 5 PR: 3 DP:2 | |
| Imaging | SD: 3 PR: 5 DP:4 | SD: 4 PR: 3 DP:3 | |
| 9 mo | PSA | SD: 3 PR: 3 DP:2 | SD: 3 PR: 2 DP:2 |
| Clinical | SD: 4 PR: 2 DP:2 | SD: 4 PR: 2 DP:1 | |
| Imaging | SD: 3 PR: 3 DP:2 | SD: 3 PR: 2 DP:2 | |
| 12 mo | PSA | SD: 3 PR: 2 DP:1 | SD: 1 PR: 1 DP:3 |
| Clinical | SD: 2 PR: 2 DP:2 | SD: 2 PR: 1 DP:2 | |
| Imaging | SD: 3 PR: 1 DP:2 | SD: 2 PR: 0 DP:3 |
DP, disease progression; PR, partial response; PSA, prostatic-specific antigen; SD, stable disease.